Premium
Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome‐9 deletion
Author(s) -
Baud Eric,
Catilina Pierre,
Boiteux JeanPaul,
Big YvesJean
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980911)77:6<821::aid-ijc3>3.0.co;2-w
Subject(s) - loss of heterozygosity , pathology , locus (genetics) , bladder cancer , biology , microsatellite , chromosome 9 , urinary bladder , allele , chromosome , cancer , genetics , gene , medicine
Loss of heterozygosity (LOH) on chromosome 9 is the most frequent genetic alteration in bladder cancer identified to date, suggesting the presence of key gene(s) for this pathology. In this study, we examined 44 bladder tumors and 21 normal bladder samples for LOH on both arms of chromosome 9. Sixteen microsatellite markers, 12 on the short arm (encompassing 9p21‐22) and 4 on the long arm (encompassing 9q33‐34), were chosen for their highly frequent alterations in bladder cancer. LOH for at least one marker was identified in 42 tumor samples (95.5%), and 14 tumors (32%) displayed LOH for all informative tested markers. Detailed analysis showed that 2 markers on chromosome 9p (D9S157 and D9S156) had the highest frequencies of allelic loss (about 70%), independent of tumor grade and stage. The same study was performed on the 21 normal bladder mucosa samples: 50% of informative cases presented a single specific LOH at the D9S156 locus. Normal samples showing LOH at this locus were therefore screened with 3 novel microsatellite markers in the 810‐kb region incorporating D9S156. Using this marker, we found no further heterozygous loss in this region. This result allows different interpretations of the D9S156 loss in normal bladder mucosa, and suggests that D9S156 may be more an indicator of bladder epithelium impairment than a tumor‐initiation marker. Similarly, this unexpected result calls in question the interpretation of LOH studies. Int. J. Cancer 77:821–824, 1998.© 1998 Wiley‐Liss, Inc.